Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2021

Email Alerts

Stay informed and receive updates directly to your inbox.

Sign up today

Company Overview

iBio, Inc. (NYSE MKT: IBIO), is a global leader in plant-based biologics manufacturing. Its FastPharming System® combines automated hydroponics, vertical farming and glycan engineering technologies to increase speed-to-clinic of scalable, consistently high-quality monoclonal antibodies, antigens, bioinks and other recombinant proteins. iBio is leveraging its FastPharming Technologies to develop novel biopharmaceuticals for respiratory and fibrotic disease indications, among others. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBio’s FastGlycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins.

Investor Contact Information


iBio Inc.
8800 HSC Pkwy
Bryan, TX 77807
T: 979-446-0027

Investor Relations

Stephen Kilmer
T: 646-274-3580

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.